This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Clercq, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Clercq, E.

Next Article 

Clinical Microbiology Reviews, October 2003, p. 569-596, Vol. 16, No. 4
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.4.569-596.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

Erik De Clercq*

Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium

The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. Cidofovir (Vistide) has been officially approved for the treatment of CMV retinitis in AIDS patients, tenofovir disoproxil fumarate (Viread) has been approved for the treatment of HIV infections (i.e., AIDS), and adefovir dipivoxil (Hepsera) has been approved for the treatment of chronic hepatitis B. Nephrotoxicity is the dose-limiting side effect for cidofovir (Vistide) when used intravenously (5 mg/kg); no toxic side effects have been described for adefovir dipivoxil and tenofovir disoproxil fumarate, at the approved doses (Hepsera at 10 mg orally daily and Viread at 300 mg orally daily).

* Mailing address: Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgum. Phone: 32-16-33.73.41. Fax: 32-16-33.73.40. E-mail: erik.declercq{at}rega.kuleuven.ac.be.

Clinical Microbiology Reviews, October 2003, p. 569-596, Vol. 16, No. 4
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.4.569-596.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Foss, A M, Vickerman, P T, Alary, M, Watts, C H (2009). How much could a microbicide's sexually transmitted infection efficacy contribute to reducing HIV risk and the level of condom use needed to lower risk? Model estimates. Sex. Transm. Infect. 85: 276-282 [Abstract] [Full Text]  
  • Birkus, G., Kutty, N., He, G.-X., Mulato, A., Lee, W., McDermott, M., Cihlar, T. (2008). . Mol. Pharmacol. 74: 92-100 [Abstract] [Full Text]  
  • Duraffour, S., Snoeck, R., Krecmerova, M., van Den Oord, J., De Vos, R., Holy, A., Crance, J.-M., Garin, D., De Clercq, E., Andrei, G. (2007). Activities of Several Classes of Acyclic Nucleoside Phosphonates against Camelpox Virus Replication in Different Cell Culture Models. Antimicrob. Agents Chemother. 51: 4410-4419 [Abstract] [Full Text]  
  • Takenaka, K., Morgan, J. A., Scheffer, G. L., Adachi, M., Stewart, C. F., Sun, D., Leggas, M., Ejendal, K. F.K., Hrycyna, C. A., Schuetz, J. D. (2007). Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution. Cancer Res. 67: 6965-6972 [Abstract] [Full Text]  
  • Shi, M., Wang, X., De Clercq, E., Takao, S., Baba, M. (2007). Selective Inhibition of Porcine Endogenous Retrovirus Replication in Human Cells by Acyclic Nucleoside Phosphonates. Antimicrob. Agents Chemother. 51: 2600-2604 [Abstract] [Full Text]  
  • Bohl, D. L., Brennan, D. C. (2007). BK Virus Nephropathy and Kidney Transplantation. CJASN 2: S36-S46 [Abstract] [Full Text]  
  • Murakami, E., Bao, H., Ramesh, M., McBrayer, T. R., Whitaker, T., Micolochick Steuer, H. M., Schinazi, R. F., Stuyver, L. J., Obikhod, A., Otto, M. J., Furman, P. A. (2007). Mechanism of Activation of {beta}-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase. Antimicrob. Agents Chemother. 51: 503-509 [Abstract] [Full Text]  
  • Imaoka, T., Kusuhara, H., Adachi, M., Schuetz, J. D., Takeuchi, K., Sugiyama, Y. (2007). Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir. Mol. Pharmacol. 71: 619-627 [Abstract] [Full Text]  
  • Balzarini, J., Schols, D., Van Laethem, K., De Clercq, E., Hockova, D., Masojidkova, M., Holy, A. (2007). Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines. J Antimicrob Chemother 59: 80-86 [Abstract] [Full Text]  
  • Jochmans, D., Deval, J., Kesteleyn, B., Van Marck, H., Bettens, E., De Baere, I., Dehertogh, P., Ivens, T., Van Ginderen, M., Van Schoubroeck, B., Ehteshami, M., Wigerinck, P., Gotte, M., Hertogs, K. (2006). Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action. J. Virol. 80: 12283-12292 [Abstract] [Full Text]  
  • Andrei, G., Gammon, D. B., Fiten, P., De Clercq, E., Opdenakker, G., Snoeck, R., Evans, D. H. (2006). Cidofovir Resistance in Vaccinia Virus Is Linked to Diminished Virulence in Mice. J. Virol. 80: 9391-9401 [Abstract] [Full Text]  
  • Colom, A J, Teper, A M, Vollmer, W M, Diette, G B (2006). Risk factors for the development of bronchiolitis obliterans in children with bronchiolitis. Thorax 61: 503-506 [Abstract] [Full Text]  
  • Dal Pozzo, F., Andrei, G., Holy, A., Van Den Oord, J., Scagliarini, A., De Clercq, E., Snoeck, R. (2005). Activities of Acyclic Nucleoside Phosphonates against Orf Virus in Human and Ovine Cell Monolayers and Organotypic Ovine Raft Cultures. Antimicrob. Agents Chemother. 49: 4843-4852 [Abstract] [Full Text]  
  • Andrei, G., van den Oord, J., Fiten, P., Opdenakker, G., De Wolf-Peeters, C., De Clercq, E., Snoeck, R. (2005). Organotypic Epithelial Raft Cultures as a Model for Evaluating Compounds against Alphaherpesviruses. Antimicrob. Agents Chemother. 49: 4671-4680 [Abstract] [Full Text]  
  • D'Cruz, O. J., Uckun, F. M. (2005). Stampidine: a selective oculo-genital microbicide. J Antimicrob Chemother 56: 10-19 [Abstract] [Full Text]  
  • Wan, W. B., Beadle, J. R., Hartline, C., Kern, E. R., Ciesla, S. L., Valiaeva, N., Hostetler, K. Y. (2005). Comparison of the Antiviral Activities of Alkoxyalkyl and Alkyl Esters of Cidofovir against Human and Murine Cytomegalovirus Replication In Vitro. Antimicrob. Agents Chemother. 49: 656-662 [Abstract] [Full Text]  
  • De Bolle, L., Naesens, L., De Clercq, E. (2005). Update on Human Herpesvirus 6 Biology, Clinical Features, and Therapy. Clin. Microbiol. Rev. 18: 217-245 [Abstract] [Full Text]  
  • Legoff, J., Guerot, E., Ndjoyi-Mbiguino, A., Matta, M., Si-Mohamed, A., Gutmann, L., Fagon, J.-Y., Belec, L. (2005). High Prevalence of Respiratory Viral Infections in Patients Hospitalized in an Intensive Care Unit for Acute Respiratory Infections as Detected by Nucleic Acid-Based Assays. J. Clin. Microbiol. 43: 455-457 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»